"RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease."
"AMT-130's Phase I/II 36-month data showed statistically significant 75% slowing in disease progression on cUHDRS (p=0.003) and 60% slowing on TFC (p=0.033). The FDA's January 2026 directive requires a full randomized, double-blind, sham surgery-controlled Phase III trial before any marketing application, and uniQure has a Type B meeting with the FDA planned for Q2 2026 to discuss Phase III study design."
"The stock currently trades at $16.52, well below both price targets. The consensus analyst target sits at $28.45, with 10 buy ratings and 3 holds across the coverage universe. The stock has surged 53.33% over the past week as the upgrade cycle took hold, though it remains down 32.72% year-to-date from its January levels."
Three clinical-stage biotechnology companies are receiving analyst upgrades based on asymmetric upside potential where market valuations have not fully incorporated success probabilities. uniQure received dual upgrades from RBC Capital and Wells Fargo following FDA leadership changes, with analysts assigning 50% approval odds to AMT-130 for Huntington's disease treatment. The drug demonstrated 75% slowing in disease progression in Phase I/II data. uniQure trades at $16.52 against consensus target of $28.45, with strong cash position of $622.5M extending runway to H2 2029. Syndax and Erasca similarly present binary catalysts where analysts perceive market underpricing of clinical success potential.
#biotech-upgrades #clinical-trial-catalysts #fda-regulatory-decisions #huntingtons-disease-treatment #binary-event-investing
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]